IDEAYA BIOSCIENCES INC (IDYA)
US45166A1025 - Common Stock
We assign a fundamental rating of 4 out of 10 to IDYA. IDYA was compared to 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IDYA as it has an excellent financial health rating, but there are worries on the profitability. IDYA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IDYA has reported negative net income.
IDYA had a negative operating cash flow in the past year.
IDYA had negative earnings in each of the past 5 years.
IDYA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
IDYA's Return On Assets of -17.40% is amongst the best of the industry. IDYA outperforms 84.79% of its industry peers.
Looking at the Return On Equity, with a value of -18.19%, IDYA belongs to the top of the industry, outperforming 88.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.4% | ||
| ROE | -18.19% | ||
| ROIC | N/A |
ROA(3y)-15.19%
ROA(5y)-18.86%
ROE(3y)-17.16%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IDYA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IDYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IDYA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IDYA has more shares outstanding
There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 66.57 indicates that IDYA is not in any danger for bankruptcy at the moment.
IDYA has a better Altman-Z score (66.57) than 98.46% of its industry peers.
IDYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 66.57 |
ROIC/WACCN/A
WACC9.14%
2.3 Liquidity
IDYA has a Current Ratio of 19.65. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 19.65, IDYA belongs to the best of the industry, outperforming 95.38% of the companies in the same industry.
IDYA has a Quick Ratio of 19.65. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 19.65, IDYA belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.65 | ||
| Quick Ratio | 19.65 |
3. Growth
3.1 Past
The earnings per share for IDYA have decreased strongly by -41.73% in the last year.
The Revenue for IDYA has decreased by -54.09% in the past year. This is quite bad
IDYA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.17% yearly.
EPS 1Y (TTM)-41.73%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-4%
Revenue 1Y (TTM)-54.09%
Revenue growth 3Y6.17%
Revenue growth 5YN/A
Revenue growth Q2Q-2.44%
3.2 Future
The Earnings Per Share is expected to grow by 28.92% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 90.14% on average over the next years. This is a very strong growth
EPS Next Y-13.63%
EPS Next 2Y2.53%
EPS Next 3Y-3.46%
EPS Next 5Y28.92%
Revenue Next Year-32.41%
Revenue Next 2Y94.92%
Revenue Next 3Y45.58%
Revenue Next 5Y90.14%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IDYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IDYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as IDYA's earnings are expected to decrease with -3.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.53%
EPS Next 3Y-3.46%
5. Dividend
5.1 Amount
IDYA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IDEAYA BIOSCIENCES INC
NASDAQ:IDYA (5/6/2024, 7:06:54 PM)
After market: 43.09 0 (0%)43.09
+0.91 (+2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.22B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.4% | ||
| ROE | -18.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 19.65 | ||
| Quick Ratio | 19.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-41.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-13.63%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-54.09%
Revenue growth 3Y6.17%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y